UNSPSC 51273020: Mepivacaine hydrochloride

This classification denotes an anesthetic agent with the molecular formula C15H22N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4VFX2L7EM5, chemically known as 2-piperidinecarboxamide, n-(2,6-dimethylphenyl)-1-methyl- but more generally known as mepivacaine hydrochloride, which bears US NIH Compound Identifier 4062. European Medicines Agency schedules Mepivacaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03158MIG.

Most nations, for tariff and trade purposes, schedule mepivacaine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, MEPIVACAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Mepivacaine hydrochloride bears US NLM identifiers UMLS ID C0700542 and NCI Concept Code C47602. SMILES: CC1CCCC(C1NC(=O)C2CCCCN2C)C.CL.

UNSPSC 51273020 Mepivacaine hydrochloride is a Commodity code for local anesthetic pharmaceuticals, but recent state and local opportunities posted under this code show minimal direct alignment with the specific active ingredient. The available opportunities frame the code's actual procurement activity around broader pharmaceutical supply categories: generic multi-source drugs and over-the-counter products distributed through state cooperative purchasing networks, naloxone and drug deactivation systems procured for community health and emergency response, and direct-to-manufacturer prescription programs under exploration by state health agencies. State and local issuing bodies using this code span county health departments and state cooperative purchasing alliances (MMCAP, Texas HHS Commission); repeat activity emerges from Minnesota's multistate collaborative purchasing infrastructure, which coordinates across participating states including Oregon.

The recent opportunities cluster in Florida and Minnesota, with Texas health agencies conducting market research on prescription program models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across state and local government facilities, with awarded vendors effective July 1, 2026 and pricing weighted 75 percent on competitiveness, compliance with cGMP and the Drug Supply Chain Security Act, and mandatory relationships with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson). Seminole County, Florida posted IFB 60459723LAS on June 30, 2026 (due July 26, 2023) for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries, fixed-fee pricing, and a two-year initial term with optional one-year renewal. The Texas Health and Human Services Commission issued RFI HHS0017013 (April 3, 2026) to gather vendor capabilities for establishing direct-to-manufacturer prescription relationships outside traditional PBM and GPO channels. The code shows activity but limited recent solicitations explicitly named for mepivacaine hydrochloride; pricing and award values are not disclosed across these opportunities.